TABLE I.

Baseline Patient Characteristics

Parameter	Value
Age (years) at initiation of IAD: mean ± SD (range); median	66.2 ± 8 (48–85); 66
Stage at the initial diagnosis of prostate cancer
T1–2	45% (n = 43)
T3	47% (n = 45)
N1	8% (n = 8)
Combined Gleason grade
Low risk (≤6)	23% (n = 22)
Intermediate risk (7)	41% (n = 39)
High risk (8–10)	34% (n = 33)
Unknown	2% (n = 2)
PSA (ng/ml) at the initial diagnosis of prostate cancer: mean ± SD (range); median	29 ± 110.95 (2.5–947); 9.25
Primary treatment
Radical prostatectomy	80% (n = 77)
Radiation therapy	19% (n = 18)
Primary androgen deprivation therapy	1% (n = 1)
Time (months) from primary treatment to biochemical relapse: mean ± SD (range); median	26.8 ± 23.3 (1–108); 18.5
Baseline PSADT (months): mean ± SD (range); median	9.7±8.6 (1.31–53.9); 7.34
Low risk (PSADT ≥9)	34% (n = 33)
Intermediate risk (PSADT 3–9)	47% (n = 45)
High risk (PSADT<3)	19% (n = 18)
PSA level (ng/ml) before the initiation of intermittent androgen deprivation (IAD): mean ± SD (range); median	37.66 ± 101 (0.4–947); 18.8
Serum testosterone (ng/dl) before the initiation of IAD: mean ± SD (range); median	416.6 ± 190.8 (183–1,040); 395.5